Alseres Pharmaceuticals, Inc.

ALSE · OTC
Analyze with AI
12/31/2013
12/31/2012
12/31/2011
12/31/2010
Operating Activities
Net Income-$942-$1,645$0$512
Dep. & Amort.$1$1$41$59
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC-$1,293$692$852$934
Other Non-Cash$546$0-$3,378-$4,456
Operating Cash Flow-$1,687-$952-$2,485-$2,951
Investing Activities
PP&E Inv.$0$0-$2$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$884$0$0$35
Other Inv. Act.$884$0$304$0
Investing Cash Flow$884$0$301$35
Financing Activities
Debt Repay.$725$510$2,239$2,707
Stock Issued$0$0$0$0
Stock Repurch.$0-$2-$18-$8
Dividends Paid$0$0$0$0
Other Fin. Act.$175$325$0$0
Financing Cash Flow$900$833$2,221$2,699
Forex Effect$0$0$0$0
Net Chg. in Cash$97-$119$37-$216
Supplemental Information
Beg. Cash$17$136$99$315
End Cash$114$17$136$99
Free Cash Flow-$1,687-$952-$2,487-$2,951
Alseres Pharmaceuticals, Inc. (ALSE) Financial Statements & Key Stats | AlphaPilot